SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc. (SIBN) reported that its Chief Financial Officer, Anshul Maheshwari, sold a total of 4,665 shares of common stock on 2026-08-17 in two open-market transactions. Footnotes state these were “sell to cover” sales to satisfy tax withholding on vesting restricted stock units, described as non-discretionary. Following these transactions, Maheshwari’s holdings include 167,604 shares issuable upon settlement of restricted stock units.
Cadian Capital Management, LP and related parties reported a passive ownership stake in SI-BONE, Inc. common stock. As of June 30, 2026, Cadian Capital Management, LP, Cadian Capital Management GP, LLC, and Eric Bannasch (together, the reporting persons) may have been deemed to beneficially own 3,347,574 shares of SI-BONE common stock, representing approximately 7.5% of the 44,697,215 shares outstanding as of that date. The shares are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, advisory clients of Cadian Capital Management, LP, which exercises exclusive voting and investment power under investment management agreements. Each reporting person had no sole voting or dispositive power but shared voting and dispositive power over the 3,347,574 shares.
SI-BONE director Jeffrey W. Dunn exercised stock options for 20,000 shares of common stock at $4.68 per share and on the same date sold 20,000 shares at a weighted-average price of $18.4607 pursuant to a Rule 10b5-1 plan dated May 7, 2025. Following these trades he holds 106,260 shares directly, including 10,957 underlying restricted stock units, plus 81,073 shares held indirectly through a living trust.
SI-BONE reported higher revenue and a smaller loss for the quarter ended June 30, 2026. Revenue was $56.0 million, up from $48.6 million a year earlier, driven primarily by a $6.8 million increase in U.S. revenue and a 14.9% increase in procedure volumes. Gross margin was 79.5%, compared with 79.8% a year earlier, with the company citing product mix.
For the first six months of 2026, revenue was $108.6 million, up 13.2% from $95.9 million, while net loss was $8.4 million, compared with $12.7 million. Operating cash use was $1.6 million, compared with $4.7 million in the prior-year period. Cash and marketable securities were $145.9 million as of June 30, 2026, and outstanding debt was $35.6 million.
The company said over 150,000 procedures had been performed using its technologies since initial commercialization. It also entered a 102-month San Jose office lease covering 50,485 square feet, with monthly base rent of $128,737 after the first six months and up to $3.8 million of landlord reimbursement for qualifying tenant improvements.
A holder of SIBN common stock filed to potentially sell 80,000 shares through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $1,420,800.00, on or after August 3, 2026. The shares relate to an Exercise of Stock Options. In the preceding three months, 3,575 shares of common stock were sold for $54,505.17 on June 5, 2026.
SI-BONE, Inc. reported second quarter 2026 results, with worldwide revenue of $56.0 million, up 15.2% from $48.6 million a year earlier. U.S. revenue was $53.2 million, up 14.7%, and international revenue $2.8 million, up 25.9%. Gross margin was 79.5% and gross profit $44.5 million.
Operating expenses rose to $49.4 million, but operating loss improved to $4.8 million and net loss narrowed to $4.1 million, or $0.09 per share. Adjusted EBITDA increased to $2.8 million from $1.0 million, and cash and equivalents were $145.9 million at June 30, 2026, with positive cash from operations of $0.8 million. Management raised 2026 worldwide revenue guidance to $231–$233 million (~15–16% growth), kept gross margin guidance at ~79%, and reduced expected operating expense growth to ~12%.
Operationally, active U.S. physicians reached 1,715, up 19%, and trailing 12‑month average revenue per territory rose 5% to $2.2 million. The company submitted a 510(k) application for a third breakthrough device, and CMS finalized a new MS‑DRG family with higher payments for procedures using iFuse Bedrock Granite in inpatient settings.
BlackRock, Inc. filed Amendment No. 7 to a Schedule 13G reporting its passive ownership in SI-BONE, Inc. common stock. As of 06/30/2026, BlackRock’s reporting business units beneficially owned 3,558,735 shares of SI-BONE common stock, representing 8.0% of the class. BlackRock had sole voting power over 3,490,613 shares and sole dispositive power over 3,558,735 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single person has an interest in more than five percent of SI-BONE’s outstanding common shares.
SI-BONE, Inc. executive Michael A. Pisetsky, SVP Operations & Administration and Chief Legal Officer, reported open-market sales of company common stock primarily to cover taxes on vested restricted stock units. On July 2, 2026, he sold 3,134 shares in three trades at prices around $16.70 per share under a “sell to cover” arrangement, which the company notes was not a discretionary trade. His equity position continues to include 137,587 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported an open-market sale of 3,317 shares of common stock on July 2, 2026. The transactions were executed at weighted average prices of $16.7348 for 1,560 shares and $16.8017 for 1,757 shares.
According to the disclosure, these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units, using a non-discretionary “sell to cover” arrangement. After these sales, Maheshwari directly holds 256,560 shares, including 177,141 shares issuable upon settlement of restricted stock units, so the reported sales represent only a small portion of his overall equity position.
HILLEMAN JERYL L reported acquisition or exercise transactions in this Form 4 filing.
SI-BONE, Inc. director Jeryl L. Hilleman received an equity grant in the form of 10,957 restricted stock units, each representing a contingent right to one share of common stock. The units were granted at $0.00 per share as director compensation, not an open-market purchase.
These restricted stock units will vest 100% on the earlier of the company’s next annual general meeting of stockholders or one year from the vesting commencement date, assuming continued board service. Following this award, Hilleman’s reported direct holdings total 43,772 shares of common stock, including the unvested units.